XML 57 R38.htm IDEA: XBRL DOCUMENT v3.24.0.1
Acquisitions (Tables)
12 Months Ended
Dec. 31, 2023
Business Combination and Asset Acquisition [Abstract]  
Schedule of Purchase Price Allocation
The following presents the preliminary allocation of purchase price to the assets acquired and liabilities assumed in the FW Murphy acquisition, based on their estimated fair values at acquisition date:

Total
Current assets
$26,564 
Goodwill224,771 
Intangible assets275,500 
Other assets and deferred charges9,508 
Current liabilities(1,316)
Non-current liabilities(8,570)
Net assets acquired$526,457 
The following presents the allocation of purchase price to the assets acquired and liabilities assumed under the Malema acquisition, based on their estimated fair values at acquisition date:

Total
Current assets, net of cash acquired$8,985 
Property, plant and equipment2,733 
Goodwill153,082 
Intangible assets84,000 
Other assets and deferred charges1,159 
Current liabilities(4,487)
Non-current liabilities(22,010)
Net assets acquired$223,462 
The following presents, for the two acquisitions other than Malema, the allocation of purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at acquisition date:
Total
Current assets, net of cash acquired$28,435 
Property, plant and equipment4,222 
Goodwill43,682 
Intangible assets40,437 
Other assets and deferred charges3,580 
Current liabilities(19,172)
Non-current liabilities(15,142)
Net assets acquired$86,042 
The following presents the allocation of purchase price, net of cash acquired of $10,382, to the assets acquired and liabilities assumed under the RegO acquisition, based on their estimated fair values at acquisition date:
Total
Accounts receivable$33,900 
Inventories71,529 
Other current assets2,958 
Property, plant and equipment50,027 
Goodwill281,163 
Intangible assets234,000 
Other assets and deferred charges884 
Current liabilities(20,150)
Non-current liabilities(27,693)
Net assets acquired$626,618 
The following presents the allocation of purchase price to the assets acquired and liabilities assumed under the Acme Cryogenics acquisition, based on their estimated fair values at acquisition date:
Total
Current assets, net of cash acquired$25,932 
Property, plant and equipment8,640 
Goodwill167,291 
Intangible assets127,300 
Other assets and deferred charges5,057 
Current liabilities(7,286)
Non-current liabilities(34,628)
Net assets acquired$292,306 
The following presents, for the seven acquisitions other than RegO and Acme Cryogenics, the allocation of purchase price to the assets acquired and liabilities assumed, based on their estimated fair values at acquisition date:
Total
Current assets, net of cash acquired$12,751 
Property, plant and equipment8,272 
Goodwill135,932 
Intangible assets78,179 
Other assets and deferred charges4,485 
Current liabilities(15,368)
Non-current liabilities(17,389)
Net assets acquired$206,862 
Schedule of Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination
The amounts assigned to goodwill and major intangible asset classifications for all 2023 acquisitions were as follows:

Amount allocatedUseful life
(in years)
Goodwill
$224,771 na
Goodwill - non-deductible2,990 na
Customer intangibles259,700 9-15
Unpatented technology12,510 7-8
Trademarks10,960 15
$510,931 
The amounts assigned to goodwill and major intangible asset classifications for all 2022 acquisitions were as follows:
Amount allocatedUseful life
(in years)
Goodwill - non-deductible$196,764 na
Customer intangibles90,742 10-15
Patents16,000 10
Unpatented technology10,302 8
Trademarks7,393 15
$321,201 
The amounts assigned to goodwill and major intangible asset classifications for all 2021 acquisitions were as follows:
Amount allocatedUseful life
(in years)
Goodwill - tax deductible$200,117 na
Goodwill - non deductible384,269 na
Customer intangibles310,819 12-15
Patents49,056 7-12
Unpatented technology44,180 7-12
Trademarks35,424 15-16
$1,023,865 
Schedule of Pro Forma Results of Operations
The following unaudited pro forma results of operations reflect the 2021 acquisitions of RegO and Acme Cryogenics as if they had occurred on January 1, 2021. The pro forma information is not necessarily indicative of the results that actually would have occurred, nor does it indicate future operating results of the combined companies. The pro forma earnings are adjusted to reflect the comparable impact of additional depreciation and amortization expense, net of tax, resulting from the fair value measurement of tangible and intangible assets; nonrecurring acquisition-related costs, net of tax, of $5,855; and inventory step-up charges, net of tax, of $15,082. These unaudited pro forma adjustments are based upon purchase price allocations. The actual revenues and earnings for RegO and Acme Cryogenics from the date of acquisition on December 28, 2021 and December 16, 2021, respectively, to December 31, 2021 were not material.

Year Ended December 31, 2021
Revenue:
As reported$7,907,081 
Pro forma (unaudited)8,163,185 
Earnings:
As reported$1,123,818 
Pro forma (unaudited)1,145,106